The text starts here.

Research & Development

Eisai Product Creation Systems (EPCS)

The Eisai Group defines its research and development (R&D) activities as “product creation” under the belief that R&D is a cornerstone of our mission to ensure that innovative drugs demonstrated to improve patients' quality of life (QOL) are delivered to patients as early as possible. The Group's R&D organization, Eisai Product Creation Systems (EPCS), strives to create innovative drugs based on an understanding of the emotions and realities of patients in order to effectively address unmet medical needs.
EPCS combines venture-like productivity and speed with the knowledge resources of a global pharmaceutical company to establish a system that shortens development timelines so as to contribute to the treatment of diseases for which sufficient treatment does not yet exist and the creation of innovative new drugs that improve the QOL of patients and their caregivers.

EPCS Structure and Responsibilities

EPCS encompasses Production Creation Units (PCUs), Core Function Units (CFUs) and the Product Creation Headquarters.
The PCUs, which comprise five units, including units specializing in oncology and neurology, are wholly responsible for conducting the series of processes ranging from discovery of innovative drug candidates through regulatory filing and approval. The CFUs, which comprise five units, including those dedicated to chemical manufacturing and controls, drug metabolism and pharmacokinetics, and safety, take full responsibility for obtaining and maintaining world-class functional capabilities in the core functions of technology, and regulatory affairs as well as promoting new drug development in cooperation with the PCUs. A total of 10 units work together to create new products using an interactive approach. The Product Creation Headquarters are responsible for the formulation of product creation strategies, corporate portfolio management, and the promotion of product creation activities.
Through the EPCS system, the Eisai Group is striving to build an organization comprising autonomous units with clearly defined responsibilities and which are specialized in each disease or technology area so as to encourage a sense of ownership and motivate employees to increase their productivity and efficiency.

Eisai Product Creation Systems (EPCS) Overview

EPCS Prioritization and Initiatives to Shorten Development Timelines

1) Drug Development Based on Innovation

There are two key factors that are fundamental to generating innovation: creating therapeutic hypotheses that lead to the treatment of diseases, and having the modern chemistry capabilities to translate these hypotheses into viable compounds for use as therapeutic agents. In order to create hypotheses for optimal disease targets from rapidly progressing research on genome informatics and other information based on human biology, EPCS continues to bolster its external network of world-leading research institutes and scientists. Through collaborations with leaders in each field, the Group is increasing the possibility of obtaining candidates for disease targets and accurate validity assessments of those targets. Moreover, the creation of compounds for each therapeutic hypothesis is crucial for delivering valid hypotheses to patients in the form of actual innovative treatments. At EPCS, we are working to enhance our technological platform for creating compounds by expanding our diverse and unique compound library while also increasing our capacity to create not only small compounds and natural products but biologics as well.

■Eisai's Drug Creation Activities

2) Initiatives to Shorten Development Timelines and Advance Personalized Medicine

Improving success rates in clinical development and shortening development timelines are crucial to being able to create new medicines for patients as early as possible, and EPCS is promoting the thorough operation of large-scale international clinical trials in this regard. We are also focused on the advancement of personalized medicine, from biomarker discovery to the development of companion diagnostics (CoDx) used in their measurement, in order to maximize patient benefits such as high therapeutic value and reducing the risk of side effects.

Clinical Trial Data Sharing

Related Links

*For the latest information on R&D activities, please refer to the R&D section of the quarterly financial results and the accompanying reference materials.